Literature DB >> 26168921

Clinicopathological features of recurrent papillary thyroid cancer.

Jian Zhu1, Xinli Wang2, Xiaoxuan Zhang3, Peifeng Li4, Haifeng Hou5.   

Abstract

BACKGROUND: To investigate the clinicopathological features of recurrent papillary thyroid carcinoma (PTC).
METHODS: A retrospective analysis on clinical and pathological data of 34 patients with recurrent PTC was carried out. A total of 281 patients with non-recurrent PTC during the same time period were chosen as the control group.
RESULTS: Patients were divided into three groups according to the pathological subtype. The number of patients belonging to Groups 1, 2, and 3 were 28, 154, and 133, respectively. 78 patients underwent partial or whole thyroidectomy, 151 cases underwent thyroidectomy combining neck regional lymph node dissection, and 86 patients underwent thyroidectomy combining modified or radical neck dissection. Univariate analysis showed that PTC recurrence was associated with tumor size, extrathyroid invasion, initial surgery approach, lymph node metastasis, and pathological subtype (P < 0.05). Patient age, gender, complication with Hashimoto's thyroiditis, and multifocality were unrelated to PTC recurrence (P > 0.05). Multivariate analysis showed that initial surgery approach and pathological subtype perform important functions in PTC recurrence (P < 0.001). Initial surgery approach presented a negative correlation with PTC recurrence (β = -0.320, OR = 0.726). The pathological subtype was also related to PTC recurrence (β = 0.923, OR = 2.517).
CONCLUSION: PTC patients without neck dissection showed greater likelihood of postoperative recurrence. Patients with the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants showed a higher propensity for PTC recurrence after operation compared with those who did not. Tumor volume, extrathyroid invasion, and multiple lymph node metastases at the time of initial operation were also significantly related to postoperative recurrence. Follow-up supervision must be enhanced after initial treatment to mitigate PTC recurrence in susceptible patients. Effective and standard treatments must be adopted immediately after the discovery of recurrence.

Entities:  

Mesh:

Year:  2015        PMID: 26168921      PMCID: PMC4501206          DOI: 10.1186/s13000-015-0346-5

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


Background

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer; this cancer presents relatively low malignancy, good prognosis, and a 10-year survival rate of over 90 %. However, the clinical behaviors of this cancer are complex and varied. PTC is easy to spread via lymphatic ducts, which results in recurrence, metastases, and even death [1]. Recurrent PTC mainly refers to localized and distant recurrence, including recurrence of the primary tumor, lymph node metastases, invasion of the esophagus and trachea, invasion of muscles, soft tissues and nerves, and distant metastases. Many factors can affect the recurrence of thyroid cancer, and final conclusion has not yet been reached. Many researchers believe that pathological type, staging, degree of extrathyroid invasion, lymph node metastatic rate, age, and initial surgery approach may be related to thyroid cancer recurrence. This research retrospectively analyzes the clinical data of 34 patients with recurrent PTC and presents a statistical comparison with non-recurrent patients to analyze factors related to PTC recurrence. The aim of the present work is to provide clinical evidence for standardized and appropriate treatment of recurrent PTC.

Methods

Clinical data

A total of 315 patients with PTC who were admitted to Jinan Military General Hospital from January 2009 to July 2013, including 66 male patients and 249 female patients, were recruited. The male to female ratio was 1:3.8. Ages ranged from 20 years to 78 years, and the median age was 48 years. The diameter of most tumors was less than 2 cm, the proportion of which was 47.1 % in the recurrent group and 85.8 % in the non-recurrent group. Moreover, 10.5 % (33 cases) of the patients presented extrathyroid invasion, and 42.2 % (133 cases) of the patients were found with lymph node metastases at the time of initial surgery. The tumors of 44.4 % (140 cases) of the patients showed multifocality, and 25.1 % (79 cases) of the patients had Hashimoto's thyroiditis (HT) (Table 1). This study received the approval of the ethics committee of the General Hospital of Jinan Military Command (No. 2013ZD01).
Table 1

Clinicopathological features of patients with recurrent and non-recurrent PTC

Clinicopathological featureRecurrent groupNon-recurrent group χ 2 P
(N = 34)(N = 281)
Age/year0.320.574
<4514130
≥4520151
Gender3.110.078
Male1155
Female23226
Tumor size34.76<0.001
<13130
≥1- < 213111
≥21840
Initial surgery approach11.390.003
First type1662
Second type14137
Third type482
Extra thyroidal invasion22.15<0.001
Yes1221
No22260
Coexistent Hashimoto’s thyroiditis0.380.537
Yes1069
No24212
Lymphatic metastasis10.100.001
Yes23110
No11171
Multifocality0.000.968
Yes15125
No19156
Pathological subtype34.45<0.001
Group 11117
Group 220134
Group 33130
Clinicopathological features of patients with recurrent and non-recurrent PTC

Pathological subtype of PTC

Recruited PTC patients were divided into three groups. Patients with the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants with higher invasiveness, higher probability of recurrence, and metastases were classified into Group 1. Patients with the follicular, clear cell, and conventional papillary carcinoma variants with similar prognosis were classified into Group 2. Patients with papillary microcarcinoma were classified into Group 3.

Initial surgery approach

The methods of primary lesion dissection used in this research included thyroid lobectomy with or without isthmectomy and total/near-total thyroidectomy. The methods of lymph node dissection included central compartment node dissection, selective neck dissection, modified neck dissection, and radical neck dissection. During statistical analysis, thyroid lobectomy with or without isthmectomy and total/near-total thyroidectomy were classified as the first type of surgical approach. Surgical approaches belonging to the first type combined with central compartment node dissection, selective neck dissection, and wide dissection of metastatic lesions were classified as the second type of surgical approach. Finally, approaches combining modified neck dissection and radical dissection were classified as the third type of surgical approach.

Statistical analysis

SPSS 17.0 software was used for statistical analysis. In addition, χ2-test and multivariate analysis using Cox proportional hazards modeling were carried out. Factors that may be related to PTC recurrence, including gender, age, tumor size, initial surgery approach, lymph node metastasis, number of lesions, complication with HT, extrathyroid invasion, and pathological subtype, were evaluated. P < 0.05 was considered statistically significant difference.

Results

Clinicopathological information

The clinicopathological information of PTC patients is given in Table 1, and the comparisons between patients with recurrence and non-recurrence were carried out. 34 recurrent patients (11 males and 23 females) were investigated in this study. The male to female ratio was 1:2.1. Ages ranged from 24 years to 72 years old, and the median age was 46 years old. Postoperative recurrence intervals from initial surgery ranged from five months to 18 years, with a median of 46 months. Twelve patients (35.3 %) showed postoperative recurrence within two years, 14 patients (41.2 %) showed postoperative recurrence within two to five years, and eight patients (23.5 %) showed postoperative recurrence over five years later. Recurrence occurred once in 29 patients (85.3 %), twice in 4 patients (11.8 %), and thrice in 1 patient (2.9 %). Two hundred eighty-one non-recurrent PTC patients were classified into the control group (55 males and 226 females); in this group, the male to female ratio was 1:4.1, the age of onset ranged from 20 years to 78 years old, and the median age was 48 years. Patients were divided into three groups according to the pathological subtype. The number of patients belonging to Groups 1, 2, and 3 among the 34 recurrent patients were 11, 20, and 3, respectively. The number of non-recurrent patients belonging to Groups 1, 2, and 3 were 17, 134, and 130 (Table 2), respectively. Among the 34 recurrent patients, 16 patients were treated using surgeries of the first type, 14 patients were treated using surgeries of the second type, and 4 patients were treated using surgeries of the third type. The numbers of non-recurrent patients treated by the first, second, and third types of surgery were 62, 137, and 82, respectively.
Table 2

Pathological subtypes of PTC

Pathological subtypeRecurrent groupNon-recurrent group
ConventionalPTC20121
Oncocytic variant711
Clear cell variant04
Follicular variant09
Tall cell variant10
Columnar cell variant34
Diffuse sclerosing variant02
Papillary microcarcinoma3130
Pathological subtypes of PTC

Univariate analysis of factors related to PTC recurrence

Tumor size, extrathyroid invasion, initial surgery approach, lymph node metastases, and pathological subtype showed statistical differences between the recurrent and non-recurrent groups (P < 0.05, Table 1). Larger tumors showed significantly increased risk of recurrence. The recurrence rate of micro-PTC was 2.3 % (3/133) and reached 31.0 % (18/58) when the tumor diameter grew to ≥2 cm. The higher recurrence rates, reaching 35.3 % (12/34), were observed when extrathyroid invasion was present at the time of initial surgery. Initial surgery approach also showed a significant effect on PTC recurrence; recurrence rates could reach 20.5 % (16/78) in patients without lymph node dissection but only 4.7 % (4/86) in patients receiving radical dissection and modified dissection. The recurrence rate was 17.3 % (23/133) in patients with cervical lymph node metastasis at the time of initial surgery and only 6.0 % (11/182) in patients without metastasis. In this research, patients with the tall cell, columnar cell, and oncocytic variants showed higher recurrence rates than patients with other cell variants (Table 2). Factors such as age, gender, complication with HT, and number of lesions demonstrated no correlation with tumor recurrence (P > 0.05, Table 1).

Multivariate analysis of factors related to PTC recurrence

Multivariate analysis revealed that initial surgery approach and pathological subtype were the main factors related to PTC recurrence (P < 0.001, Table 3). Initial surgery approach was negatively correlated with PTC recurrence (β = −0.320, OR = 0.726). Thus, patients receiving conservative treatment are more likely to develop PTC recurrence than patients treated with more radical modalities. Recurrence rates decreased with increasing surgical scope. Pathological subtype also showed a close correlation with PTC recurrence (β = 0.923, OR = 2.517).
Table 3

Multivariate analysis of factors related to recurrent PTC

Clinicopathological characteristic β SE Waldχ 2 P OR95 % CI
Initial operative approach−0.3200.09322.593<0.0010.7260.605 ~ 0.871
Pathological subtype0.9230.19618.337<0.0012.5171.714 ~ 3.696
Multivariate analysis of factors related to recurrent PTC

Discussion

PTC is the most common but least aggressive histological subtype of thyroid cancer. Most patients with PTC have excellent prognosis. However, recent studies have demonstrated increasing incidence of recurrent PTC [2, 3]. Many factors can affect thyroid cancer recurrence, but final conclusions have not been reached. The results of some studies show that the pathological type, staging, degree of extrathyroid invasion, lymph node metastatic rate, age, and initial surgery approach are related to thyroid cancer recurrence [4, 5]. Our research showed that tumor size, extrathyroid invasion, initial surgery approach, lymph node metastasis, and pathological subtype demonstrate statistically significant differences between the recurrent and non-recurrent groups. By contrast, factors such as age, gender, complication with HT, and number of lesions are not correlated with tumor recurrence. Multivariate analysis results further revealed that initial surgery approach and pathological subtype are main factors related to PTC recurrence. The dissection methods of primary lesions of PTC include (1) hemithyroidectomy with or without isthmectomy, (2) total/near-total thyroidectomy, and (3) extension of surgical scope. In case of severe extrathyroid invasion, such as invasion of the esophagus, trachea, and nerves, extending the scope of surgery is required. The methods of neck dissection are as follows: (1) central compartment node dissection (unilateral or bilateral), (2) selective neck dissection, (3) functional compartmental en-bloc neck dissection, (4) modified neck dissection, and (5) radical neck dissection [6]. Mazzaferri et al. [7] found that the recurrence rate after partial thyroidectomy is nearly twice that of total and near-total thyroidectomy. By contrast, Cunningham et al. [8] revealed that the recurrence rates had no significant difference between hemithyroidectomy and total/near-total thyroidectomy groups. Monacelli et al. [9] suggested that total thyroidectomy combined with central node dissection must be performed even in the absence of risk factors and without clinically evident nodes. However, some researchers do not advocate prophylactic central neck lymphadenectomy [10]. Univariate analysis in this research showed that initial surgery approach exerts a great impact on the prognosis. For example, while 47.1 % (16/34) of the recurrent PTC patients received the first type of surgery as initial surgery, only 22.1 % (62/281) of the non-recurrent PTC patients received the first type of surgery. About 52.9 % (18/34) of the recurrent PTC patients received the second and third types of surgery. In comparison, 77.9 % (219/281) of the non-recurrent PTC patients received the second and third types of surgery as the initial surgery. Multivariate analysis revealed that initial surgery approach is the main factor related to PTC recurrence (P < 0.001); specifically, initial surgery approach demonstrated a negative correlation with PTC recurrence (β = −0.320, OR = 0.726). The recurrence rate decreased with increasing surgical scope. Non-standardized surgical approaches with inappropriately small surgical scopes could lead to tumor residue. Moreover, lesions of lymph node metastasis may be missed, thereby increasing the risk of recurrence. Possible reasons behind the inconsistency of results are as follows: (1) Differences among recruited patients. Patients receiving neck dissection showed significant metastases, whereas no cervical lymph node metastasis was discovered before the operation in patients who did not receive neck dissection. (2) Insufficient number of recruited patients. (3) Difference in surgical techniques among surgeons. Considering these factors, blindly extending or narrowing the surgical scope is irrational. The World Health Organization (WHO) histological classification of tumors has redefined the subtypes of non-conventional PTC [11]: follicular variant, oncocytic variant, diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, PTC with nodular fasciitis-like stroma, clear cell variant, and diffuse follicular variant. PTC patients of different histological subtypes may exhibit diverse clinical and biological behaviors. Subtypes including the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants have higher invasiveness and may promote higher risks of recurrence and metastases [12-14]. The prognosis of patients with the follicular and clear cell variants is similar to that of patients with conventional papillary carcinoma [15]. Thyroid microcarcinoma is a type of papillary carcinoma that is less than 1 cm in diameter with relatively low invasiveness and good prognosis [16]. This research classified histological variants according to the WHO histological classification of tumors. Patients with the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants were classified into Group 1; patients with the follicular, clear cell, and conventional PTC variants were classified into Group 2; and patients with papillary microcarcinomas were classified into Group 3. The research conducted by Boone et al. [17] showed that the recurrence rate of patients with differentiated thyroid carcinoma is lower than that of patients with other types of thyroid carcinoma. Among the differentiated thyroid carcinomas, the recurrence rate of PTC is lower than that of the follicular variant. However, 30 % of the PTC patients continue to suffer from recurrence, metastasis, and even death [18]. Univariate analysis demonstrated that pathological subtype is obviously correlated with PTC recurrence (P < 0.01). Multivariate analysis also indicated that pathological subtype is closely related to PTC recurrence (β = 0.923, OR = 2.517). The recurrence rate of PTC increased as the invasiveness of the tumor increased. Thus, close follow-up must be carried out in patients with the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants. Effective treatment measures must be taken once recurrence is discovered. Various results are reported in the literature regarding the effect of lymph node metastases on PTC recurrence. Some studies indicate that lymph node metastases do not affect PTC recurrence [19]. However, some researchers have found that the number of lymph node metastases is associated with postoperative recurrence or re-metastasis. Thus, lymph node metastasis has become an important factor affecting the prognosis and recurrence of thyroid carcinoma [20]. The results of this research revealed statistically significant differences in lymph node metastases between the recurrent and non-recurrent groups. Patients with lymph node metastases at the time of initial surgery are more likely to suffer recurrence than those without metastases. The correlation of cervical lymph node metastases with recurrence needs to be confirmed through large-sample and long-term studies. Of the 34 recurrent PTC patients in the group, postoperative recurrence intervals ranged from five months to 18 years, with a median time of 46 months. Recurrence was observed to occur within a short period of time. The majority of PTC patients, for example, showed recurrence within two to five years from surgery. Furthermore, recurrence may also occur more than once. Therefore, PTC patients must have regular reexamination with frequent follow-ups within five years after the first treatment. Ultrasound examination must be performed at least once a year within five years after the first treatment for timely discovery of tumor recurrence.

Conclusions

In conclusion, initial surgery approach, tumor size, extrathyroid invasion, lymph node metastases, and pathological type may be related to PTC recurrence. However, opinions on the resection scope of PTC differ. Surgical indications and methods vary on a case-to-case basis. According to Untch et al. [21], lobectomy for patients with low risk is suitable. Nixon et al. [22] demonstrated no difference in the 10-year survival rate of patients with low-risk highly differentiated thyroid carcinoma and those receiving lobectomy and total thyroidectomy. Doctors must consider patient compliance during follow-ups when evaluating whether or not the patient must receive thyroid lobectomy. For individuals with poor economic means, low education levels, poor knowledge about their condition, and inability to accomplish regular follow-up, complete thyroidectomy may be a suitable option. The most appropriate resection scope for PTC can be determined by considering the thoroughness of operation, the functions of the thyroid and parathyroid glands, and the relationships between important anatomical positions. Enhanced follow-up and postoperative reexamination must be carried out in patients with increased risk of recurrence. Effective and regular treatments must be administered once recurrence is discovered.

Consent

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
  21 in total

1.  Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy.

Authors:  Iain J Nixon; Ian Ganly; Snehal G Patel; Frank L Palmer; Monica M Whitcher; Robert M Tuttle; Ashok Shaha; Jatin P Shah
Journal:  Surgery       Date:  2011-10-14       Impact factor: 3.982

2.  Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  Lateral neck recurrence from papillary thyroid carcinoma: Predictive factors and prognostic significance.

Authors:  Davide Giordano; Andrea Frasoldati; Jan L Kasperbauer; Enrico Gabrielli; Carmine Pernice; Michele Zini; Corrado Pedroni; Silvio Cavuto; Verter Barbieri
Journal:  Laryngoscope       Date:  2014-12-15       Impact factor: 3.325

4.  Survival discriminants for differentiated thyroid cancer.

Authors:  M P Cunningham; R B Duda; W Recant; J S Chmiel; J A Sylvester; A Fremgen
Journal:  Am J Surg       Date:  1990-10       Impact factor: 2.565

5.  Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer.

Authors:  John C Watkinson; Jayne A Franklyn; Julie F C Olliff
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

6.  Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.

Authors:  Jamal Zidan; Drumea Karen; Moshe Stein; Edward Rosenblatt; Walid Basher; Abraham Kuten
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.

Authors:  Margo Shoup; Alexander Stojadinovic; Aviram Nissan; Ronald A Ghossein; Sam Freedman; Murray F Brennan; Jatin P Shah; Ashok R Shaha
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

9.  Prophylactic central neck lymphadenectomy in high risk patients with T1 or T2 papillary thyroid carcinoma: is it useful?

Authors:  Daniele Delogu; Ilia Patrizia Pisano; Carlo Pala; Fabio Pulighe; Salvatore Denti; Antonio Cossu; Mario Trignano
Journal:  Ann Ital Chir       Date:  2014 May-Jun       Impact factor: 0.766

Review 10.  Well-differentiated carcinoma of the thyroid.

Authors:  Ryan T Boone; Chun-Yang Fan; Ehab Y Hanna
Journal:  Otolaryngol Clin North Am       Date:  2003-02       Impact factor: 3.346

View more
  11 in total

1.  The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Authors:  Fei Wang; Xiaolong Yu; Xiaopei Shen; Guangwu Zhu; Yueye Huang; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Shiguo Liu; Jiajun Zhao; Shihua Zhao; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

2.  Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.

Authors:  Ryuta Nagaoka; Aya Ebina; Kazuhisa Toda; Tomoo Jikuzono; Marie Saitou; Masaomi Sen; Hiroko Kazusaka; Mami Matsui; Keiko Yamada; Hiroki Mitani; Iwao Sugitani
Journal:  World J Surg       Date:  2021-06-07       Impact factor: 3.352

3.  Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction.

Authors:  Yi Li; Yue Zang; Tianda Fan; Zhaochen Li; Anzi Li; Wei Lv; Qingqing Wang; Qinglan Li; Yuanyuan Li; Quan Li; Zhongsheng Sun; Huajing Teng
Journal:  Comput Struct Biotechnol J       Date:  2022-05-16       Impact factor: 6.155

4.  ¹⁸F-FDG PET/CT-Guided Clinical Management of the Rare Aggressive "Columnar-Cell" Variant of Papillary Thyroid Cancer.

Authors:  Manuela Vadrucci; Giovanni Serio; Alberto Baroli
Journal:  Endocrinol Metab (Seoul)       Date:  2016-05-13

5.  3D-Printed Template-Guided 125I Seed Brachytherapy: A Salvage Approach for Locoregional Refractory Recurrence of Papillary Thyroid Cancer.

Authors:  Zhen Gao; Hongtao Zhang; Lijuan Zhang; Huimin Yu; Xuemin Di; Zeyang Wang; Zezhou Liu; Aixia Sui; Juan Wang; Gaofeng Shi
Journal:  Eur Thyroid J       Date:  2021-10-04

6.  Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies.

Authors:  Shinje Moon; Hye Soo Chung; Jae Myung Yu; Hyung Joon Yoo; Jung Hwan Park; Dong Sun Kim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2018-12

7.  125I Seed Brachytherapy for Refractory Loco-Regional Recurrence of Non-Anaplastic Thyroid Cancer.

Authors:  Huimin Yu; Hongtao Zhang; Zhen Gao; Xiaoli Liu; Lijuan Zhang; Xuemin Di; Zeyang Wang; Zezhou Liu; Aixia Sui; Juan Wang; Gaofeng Shi
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 5.738

8.  Image-guided high-dose-rate interstitial brachytherapy - a valuable salvage treatment approach for loco-regional recurrence of papillary thyroid cancer.

Authors:  Ning Wu; Hongfu Zhao; Dongmei Han; Guanghui Cheng; Zhipeng Zhao; Yuxin Ge
Journal:  J Contemp Brachytherapy       Date:  2016-04-07

9.  Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.

Authors:  Lihua Huang; Xuming Wang; Xuan Huang; Huawei Gui; Yan Li; Qiongxia Chen; Dongling Liu; Lijiang Liu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  Clinicopathologic characteristics and outcomes of papillary thyroid carcinoma in younger patients.

Authors:  Yi Lu; Lin Jiang; Chao Chen; Haitao Chen; Qinghua Yao
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.